Bollywood A-listers Shah Rukh Khan, Ajay Devgn, and Tiger Shroff have formally submitted their replies to the show-cause notices issued by the Maharashtra Food and Drug Administration (FDA). The regulatory authority had issued notices regarding their involvement in promotional campaigns for cardamom (elaichi) products under brands predominantly recognized for pan masala and tobacco manufacturing. The FDA’s action stems from concerns over surrogate advertising practices that indirectly promote health-hazardous products to impressionable audiences.
Maharashtra FDA’s Crackdown on Surrogate Advertising
The Food and Drug Administration of Maharashtra has significantly intensified its monitoring of surrogate advertisements across print, digital, and broadcast media. Authorities emphasized that while cardamom products themselves are permissible for sale, using brand names, logos, colors, and styling identical to gutkha or pan masala lines creates an indirect promotional bridge. According to health regulations, surrogate marketing circumvents existing bans on advertising tobacco and related substances, prompting regulatory authorities to seek formal explanations from public figures endorsing such brands.
Legal Responses and Arguments Presented by the Actors
In their official representations submitted through legal counsel, the actors clarified their positions regarding contractual agreements and promotional terms. The responses highlighted that the endorsements were strictly restricted to mouth-freshener cardamom products, which are legally permissible food items under standard regulations. Furthermore, the legal teams argued that the actors did not promote tobacco, gutkha, or nicotine-containing products in any capacity. They emphasized full compliance with prevailing advertisement guidelines and standard commercial licensing regulations.
Regulatory Evaluation and Potential Legal Outcomes
The Maharashtra FDA is currently reviewing the formal responses alongside legal experts and regulatory officers. Authorities are evaluating whether the promotional imagery and branding violate statutory provisions governing food safety, public health guidelines, and consumer protection acts. Should the regulatory body find the explanations insufficient, further procedural directives or administrative actions could follow under food safety regulations and advertisement standards codes.
Public Reaction and Industry Impact
The regulatory intervention has reignited a nationwide dialogue regarding celebrity endorsements and brand accountability. Industry analysts suggest that increased regulatory scrutiny will compel celebrities and marketing agencies to exercise heightened due diligence when signing commercial agreements. Public health advocates have welcomed the regulatory vigilance, emphasizing the necessity of preventing surrogate promotions of harmful products through high-profile celebrity figures.
